Desferrioxamine and dextromethorphan combination exhibited synergistic effect and reversed the catalepsy behaviour in 6-hydroxydopamine hydroydopamine administered rats through regulating brain glutamate levels

J Pharm Pharmacol. 2019 Aug;71(8):1271-1281. doi: 10.1111/jphp.13109. Epub 2019 May 29.

Abstract

Objective: To investigate the effect of desferrioxamine (DFO) and dextromethorphan (DXM) combination in animal model of Parkinson's disease (PD).

Methods: The PD was induced in rats through intracerebroventricular administration of 6-hydroxydopamine (6-OHDA) using stereotaxic apparatus. The animals were subjected to behavioural assessments and neurobiochemicals estimation followed by immunohistochemistry staining of neuron specific enolase (NSE) in striatum.

Key findings: Desferrioxamine and DXM combination has significantly reversed the catalepsy behaviour and elevated the antioxidant enzymes (SOD, CAT, GSH) and dopamine levels. Interestingly, the level of glutamate, nitric oxide, cytokines (IL-1β, TNF-α) and NSE expressions were found to be decreased in striatum region of 6-OHDA-administered rats. The combination of DFO and DXM has shown synergism in most of the parameters studied, when compared to per se treatment.

Conclusions: The reversal of catalepsy behaviour represents the protective effect of above combination on dopamine neurons in striatum from 6-OHDA toxicity. The mechanism of DFO and DXM combination might be attributed through attenuation of glutamate-induced excitotoxicity in neurons through ameliorating the reactive oxygen species and pro-inflammatory cytokines release. Treatment with DFO and DXM combination could control the multiple events in the pathogenesis of PD.

Keywords: catalepsy; cytokines; excitotoxicity; glutamate; striatum; synergism.

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Catalepsy / drug therapy*
  • Catalepsy / metabolism
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Deferoxamine / pharmacology*
  • Dextromethorphan / pharmacology*
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dopaminergic Neurons / drug effects
  • Drug Combinations
  • Drug Synergism
  • Glutamic Acid / metabolism*
  • Hydroxydopamines / pharmacology*
  • Male
  • Neuroprotective Agents / pharmacology
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Rats
  • Rats, Wistar

Substances

  • Antioxidants
  • Drug Combinations
  • Hydroxydopamines
  • Neuroprotective Agents
  • Glutamic Acid
  • Dextromethorphan
  • Deferoxamine
  • Dopamine